Scott Gottlieb, commissioner of the Food and Drug Administration

Following new criticism against medical-device approvals, the Food and Drug Administration has announced that it plans to revamp the way it considers pending products.

Regulators will place a higher emphasis on ensuring safety, effectiveness and newness, according to Monday’s announcement.

“We’re seizing the chance to make a generational change in the framework for 510(k) reviews — one that advances its best features while making sure it keeps pace with modern innovation,” FDA Commissioner Scott Gottlieb said in a statement.

The announcement comes in the wake of an investigation by more than 50 media organizations. Their investigation noted that more than 1.7 million injuries and nearly 83,000 deaths suspected of being linked to medical devices had been reported to federal regulators in the past decade.